Search by Drug Name or NDC
NDC 49702-0258-37 Triumeq PD Details
Triumeq PD
Triumeq PD is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ViiV Healthcare Company. The primary component is .
MedlinePlus Drug Summary
The combination of abacavir, dolutegravir, and lamivudine is used alone or along with other medications to treat HIV infection in certain adults and children who weigh at least 88 lb (40 kg). Abacavir and lamivudine are in a class of medications called nucleoside analogue reverse transcriptase inhibitors (NRTIs) and dolutegravir is in a class of medications called integrase strand transfer inhibitors (INSTIs). They work by decreasing the amount of HIV in your blood and increasing the number of immune cells that help fight infections in your body. Although abacavir, dolutegravir, and lamivudine will not cure HIV, these medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of getting or transmitting the HIV virus to other people.
Related Packages: 49702-0258-37Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Abacavir, Dolutegravir, and Lamivudine
Product Information
| NDC | 49702-0258 |
|---|---|
| Product ID | 49702-258_c6caf251-b34f-4846-a477-576354b96d15 |
| Associated GPIs | 12109903157320 |
| GCN Sequence Number | 083242 |
| GCN Sequence Number Description | abacavir/dolutegravir/lamivudi TAB SUSP 60-5-30 MG ORAL |
| HIC3 | W5Z |
| HIC3 Description | ANTIRETROVIRAL-NRTIS AND INTEGRASE INHIBITORS COMB |
| GCN | 52144 |
| HICL Sequence Number | 041355 |
| HICL Sequence Number Description | ABACAVIR SULFATE/DOLUTEGRAVIR SODIUM/LAMIVUDINE |
| Brand/Generic | Brand |
| Proprietary Name | Triumeq PD |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | abacavir sulfate, dolutegravir sodium, lamivudine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | KIT |
| Route | n/a |
| Active Ingredient Strength | n/a |
| Active Ingredient Units | n/a |
| Substance Name | n/a |
| Labeler Name | ViiV Healthcare Company |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA215413 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 49702-0258-37 (49702025837)
| NDC Package Code | 49702-258-37 |
|---|---|
| Billing NDC | 49702025837 |
| Package | 1 KIT in 1 CARTON (49702-258-37) * 90 TABLET, FILM COATED in 1 BOTTLE (49702-272-59) |
| Marketing Start Date | 2022-03-30 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |